Technical Analysis for BRTX - Biorestorative Therapies Inc

Grade Last Price % Change Price Change
D 0.0047 20.51% 0.0008
BRTX closed up 21.88 percent on Friday, October 15, 2021, on approximately normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Up
Historical BRTX trend table...

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 20.51%
Crossed Above 50 DMA Bullish 20.51%
MACD Bullish Signal Line Cross Bullish 20.51%
Expansion Pivot Buy Setup Bullish Swing Setup 20.51%
Pocket Pivot Bullish Swing Setup 20.51%
Bollinger Band Squeeze Range Contraction 20.51%
BB Squeeze + Lower Band Touch Range Contraction 20.51%
BB Squeeze Started Range Contraction 20.51%
BB Squeeze + Upper Band Touch Range Contraction 20.51%
Outside Day Range Expansion 20.51%
Older End-of-Day Signals for BRTX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Possible Pocket Pivot about 6 hours ago
Up 2 ATRs about 6 hours ago
Up 1 ATR about 6 hours ago
10x Volume Pace about 6 hours ago
5x Volume Pace about 6 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Biorestorative Therapies Inc Description

BioRestorative Therapies, Inc. develops therapeutic products using cell and tissue protocols primarily involving adult stem cells. The company's two core programs are relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program includes a lead cell therapy candidate, BRTX-100 is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow and intended for the non-surgical treatment of painful lumbosacral disc disorders. The BRTX-100 utilizes proprietary technology and involves collecting a patient's bone marrow, isolating and culturing stem cells from the bone marrow, and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient's damaged disc and treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. The company have received authorization from the Food and Drug Administration to commence a Phase 2 clinical trial using BRTX-100to treat persistent lower back pain due to painful degenerative discs. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy in preclinical stage to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). In addition, the company provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; and a research agreement with Pfizer, Inc. and the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is based in Melville, New York. On March 20, 2020, BioRestorative Therapies, Inc., filed a voluntary petition


Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biology Life Sciences Pain Surgery Stem Cells Cell Biology Cell Therapy Obesity Therapeutic Product Food And Drug Administration Therapeutic Products Spine Skeletal System Pfizer Metabolic Disorders Back Pain Bone Marrow Endocrine System Adult Stem Cell Bone Rtx Adipose Tissue Mesenchymal Stem Cell Surgical Treatment Therapeutic Invasive Procedures Rohto Pharmaceutical

Is BRTX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 0.0464
52 Week Low 0.0028
Average Volume 28,056,039
200-Day Moving Average 0.0082
50-Day Moving Average 0.0036
20-Day Moving Average 0.0034
10-Day Moving Average 0.0034
Average True Range 0.0009
ADX 22.68
+DI 23.6842
-DI 9.2105
Chandelier Exit (Long, 3 ATRs) 0.0014
Chandelier Exit (Short, 3 ATRs) 0.0057
Upper Bollinger Bands 0.0038
Lower Bollinger Band 0.0030
Percent B (%b) 1.13
BandWidth 23.5294
MACD Line -0.0002
MACD Signal Line -0.0002
MACD Histogram 0.0
Fundamentals Value
Market Cap 171.56 Thousand
Num Shares 44 Million
Price-to-Sales 1.04
Price-to-Book 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.0056
Resistance 3 (R3) 0.0054 0.0048 0.0053
Resistance 2 (R2) 0.0048 0.0043 0.0048 0.0052
Resistance 1 (R1) 0.0043 0.0041 0.0046 0.0045 0.0051
Pivot Point 0.0037 0.0037 0.0038 0.0037 0.0037
Support 1 (S1) 0.0032 0.0032 0.0035 0.0034 0.0027
Support 2 (S2) 0.0026 0.0030 0.0026 0.0026
Support 3 (S3) 0.0021 0.0026 0.0025
Support 4 (S4) 0.0023